

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Widner *et al.*

Serial No.: To be assigned

Group Art Unit: To be assigned

Filed: April 12, 2001

Examiner: To be assigned

For: Methods For Producing a Polypeptide in a Bacillus Cell

**PRELIMINARY AMENDMENT**

Commissioner for Patents  
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested (a marked up version pursuant to 37 C.F.R. 1.21 is attached hereto):

**IN THE SPECIFICATION**

At page 1, amend lines 6-7 to read as follows:

--This application is a divisional of pending U.S. application serial no. 09/256,377 filed on February 26, 1999, which is a continuation-in-part of U.S. Patent No. 5,955,310 issued on September 21, 1999, which are fully incorporated herein by reference.--

**IN THE CLAIMS**

Please cancel claims 1-73 without prejudice or disclaimer. Please add new claims 74-93:

74. A *Bacillus* cell comprising a nucleic acid construct which comprises (a) a "consensus" promoter having the sequence TTGACA for the "- 35" region and TATAAT for the "-10" region operably linked to a single copy of a nucleic acid sequence encoding the polypeptide and (b) an mRNA processing/stabilizing sequence located downstream of the "consensus" promoter and upstream of the nucleic acid sequence encoding the polypeptide.

75. The *Bacillus* cell of claim 74, wherein the consensus promoter is obtained from any

bacterial promoter.

76. The *Bacillus* cell of claim 75, wherein the "consensus" promoter is obtained from a *Bacillus* promoter.

77. The *Bacillus* cell of claim 74, wherein the consensus promoter is obtained from a promoter obtained from the *E. coli lac* operon, *Streptomyces coelicolor* agarase gene (*dagA*), *Bacillus lentus* alkaline protease gene (*aprH*), *Bacillus licheniformis* alkaline protease gene (subtilisin Carlsberg gene), *Bacillus subtilis* levansucrase gene (*sacB*), *Bacillus subtilis* alpha-amylase gene (*amyE*), *Bacillus licheniformis* alpha-amylase gene (*amyL*), *Bacillus stearothermophilus* maltogenic amylase gene (*amyM*), *Bacillus amyloliquefaciens* alpha-amylase gene (*amyQ*), *Bacillus licheniformis* penicillinase gene (*penP*), *Bacillus subtilis* *xylA* and *xylB* genes, *Bacillus thuringiensis* subsp. *tenebrionis* CryIIIA gene (*cryIIIA*, SEQ ID NO. 21), or prokaryotic beta-lactamase gene *spo1* bacterial phage promoter.

78. The *Bacillus* cell of claim 74, wherein the "consensus" promoter is obtained from the *Bacillus amyloliquefaciens* alpha-amylase gene (*amyQ*).

79. The *Bacillus* cell of claim 78, wherein the "consensus" *amyQ* promoter has the nucleic acid sequence of SEQ ID NO. 26 or SEQ ID NO. 27.

80. The *Bacillus* cell of claim 74, wherein the mRNA processing/stabilizing sequence is the *cryIIIA* mRNA processing/stabilizing sequence.

81. The *Bacillus* cell of claim 74, wherein the mRNA processing/stabilizing sequence is the SP82 mRNA processing/stabilizing sequence.

82. The *Bacillus* cell of claim 74, which contains one or more copies of the nucleic acid construct.

83. The *Bacillus* cell of claim 74, which contains one copy of the nucleic acid construct.

84. The *Bacillus* cell of claim 74, wherein the nucleic acid construct further comprises a selectable marker gene.

85. The *Bacillus* cell of claim 74, which contains no selectable marker gene.
86. The *Bacillus* cell of claim 74, wherein the nucleic acid sequence encodes a polypeptide heterologous to the *Bacillus* cell.
87. The *Bacillus* cell of claim 74, wherein the polypeptide is a hormone, enzyme, receptor, antibody, or reporter.
88. The *Bacillus* cell of claim 87, wherein the enzyme is an oxidoreductase, transferase, hydrolase, lyase, isomerase, or ligase.
89. The *Bacillus* cell of claim 87, wherein the enzyme is an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, a pectinolytic enzyme, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, or xylanase.
90. The *Bacillus* cell of claim 74, wherein the nucleic acid sequence is contained in the chromosome of the *Bacillus* cell.
91. The *Bacillus* cell of claim 74, wherein the nucleic acid sequence is contained on an extrachromosomal element.
92. The *Bacillus* cell of claim 74, which is a *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus clausii*, *Bacillus coagulans*, *Bacillus firmus*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus pumilus*, *Bacillus stearothermophilus*, *Bacillus subtilis*, or *Bacillus thuringiensis* cell.
93. The *Bacillus* cell of claim 74, which *Bacillus subtilis* cell.

#### REMARKS


This application is a divisional of pending U.S. application serial no. 09/256,377 filed on February 26, 1999, which is a continuation-in-part of U.S. Patent No. 5,955,310 issued on

September 21, 1999, which application and patent are fully incorporated herein by reference.

Claims 1-73 have been cancelled and new claims 74-93 added.

Date: April 12, 2001

Respectfully submitted,

A handwritten signature in cursive script, reading "Robert L. Starnes". The signature is written in black ink and is positioned above a horizontal line.

Robert L. Starnes, Reg. No. 41,324  
Novozymes Biotech, Inc.  
1445 Drew Avenue  
Davis, CA 95616  
(530) 757-8100

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Widner *et al.*

Serial No.: To be assigned

Group Art Unit: To be assigned

Filed: April 12, 2001

Examiner: To be assigned

For: Methods For Producing a Polypeptide in a Bacillus Cell

**VERSION WITH MARKINGS TO SHOW CHANGES MADE UNDER 37 C.F.R. 1.21**

Commissioner for Patents  
Washington, DC 20231

Sir:

Below is a marked-up version of the amendment made in the accompanying amendment.


**IN THE SPECIFICATION:**

At page 1, amend lines 6-7 to read as follows:

**Cross-Reference to Related Applications**

~~This application is a continuation-in-part of application serial no. 09/031,442 filed February 26, 1998, the contents of which are fully incorporated herein by reference.~~ This application is a divisional of pending U.S. application serial no. 09/256,377 filed on February 26, 1999, which is a continuation-in-part of U.S. Patent No. 5,955,310 issued on September 21, 1999, which are fully incorporated herein by reference.

Respectfully submitted,



Robert L. Starnes, Reg. No. 41,324  
Novozymes Biotech, Inc.  
1445 Drew Avenue  
Davis, CA 95616  
(530) 757-8100

Date: April 12, 2001